Riverhead Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Riverhead Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,400	Closed	-$3K	–	1521
2018 Q4	$3K	Sell	1,400 -1,423	-50%	-$12.5K	﹤0.01%	1487
2018 Q3	$42K	Sell	2,823 -292	-9%	-$4.64K	﹤0.01%	1505
2018 Q2	$47K	Buy	3,115 +2,828	+985%	+$48K	﹤0.01%	1469
2018 Q1	$5K	Buy	+287	New	+$5.02K	﹤0.01%	1538

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Riverhead Capital Management's SNNA Position: Q1 2019 in Review

Riverhead Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2019, closing a stake of 1,400 shares — an estimated $3K sold.

Riverhead Capital Management first reported a position in SNNA in Q1 2018 and held it in 4 quarters. The position peaked at $47K in Q2 2018. 57 funds tracked by Wall St. Rank hold SNNA as of Q1 2019.

Riverhead Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Riverhead Capital Management sold 1,400 Sienna Biopharmaceuticals, Inc. shares in Q1 2019, an estimated $3K.
Riverhead Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
Riverhead Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $47K in Q2 2018.
57 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2019.

Based on Riverhead Capital Management's 13F filing for Q1 2019, filed 13 May 2019.